Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy
undefined
Sep 15, 2020
www.globenewswire.com
Adicet Announces Completion of Merger with resTORbio
#Acquisition #Public Trading #Management Changes
Apr 29, 2020
www.globenewswire.com
resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology
#Acquired-by, Investment
Oct 3, 2019
en.globes.co.il
aMoon invests in $80m Adicet Bio financing round
#Investment
Oct 2, 2019
www.calcalistech.com
Allogenic Immunotherapy Company Adicet Bio Raises $80 Million
#Investment
Jan 27, 2016
en.globes.co.il
Adicet buys Applied Immune Technologies
#Acquisition #Investment
About
Adicet Bio Inc is a preclinical-stage biotechnology company engaged in the design and development of immunotherapies for cancer and other disease indications, with a focus on novel universal immune cell therapies. The company's development is based on gamma delta T cells engineered with chimeric antigen receptors or T-cell receptors.
In 2016, Adicet Bio Inc acquired Israeli company Applied Immune Technologies (AIT), which develops immunotherapies. AIT, today called Adicet Bio Israel, continues its operations in Israel as Adicet's wholly owned subsidiary.